Chief Executive Officer Appointment
Chief Executive Officer Appointment (final)
Chief Executive Officer Appointment (final)
Additional Phase 1 data suggest MPL may inhibit motor neurone disease (final)
PharmAust Completes Cohort 3 Pharmacokinetics in MND Patients
Appendix 4C and Quarterly Update – June 2023
MND Trial Successfully Completes 3rd Patient Cohort (final)
PAA Canine Study Update – July 2023_KA & SW
Results show MPL suppresses biomarkers associated with MND (final)
Louie the beagle surpasses one year on MPL (final)
230704_MND Biomarkers and Pharmacodynamics Results (final)